A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
1
Issued Date
2026-01-01
Resource Type
ISSN
14796694
eISSN
17448301
Scopus ID
2-s2.0-105038027356
Pubmed ID
42037107
Journal Title
Future Oncology
Volume
22
Issue
11
Start Page
1247
End Page
1262
Rights Holder(s)
SCOPUS
Bibliographic Citation
Future Oncology Vol.22 No.11 (2026) , 1247-1262
Suggested Citation
Lu S., Kato T., Dong X., Ahn M.J., Quang L.V., Soparattanapaisarn N., Inoue T., Wang C.L., Huang M., Yang J.C.H., Cobo M., Özgüroğlu M., Casarini I., Sriuranpong V., Cronemberger E., Takahashi T., Runglodvatana Y., Chen M., Huang X., Grainger E., Ghiorghiu D., van der Gronde T., Ramalingam S.S. A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery. Future Oncology Vol.22 No.11 (2026) , 1247-1262. 1262. doi:10.1080/14796694.2026.2652543 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/116746
Title
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery
Author's Affiliation
University of Chinese Academy of Sciences
West China School of Medicine/West China Hospital of Sichuan University
Tongji Medical College of Huazhong University of Science and Technology
National Taiwan University Hospital
Chang Gung University
Samsung Medical Center, Sungkyunkwan university
AstraZeneca
Siriraj Hospital
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine
Osaka International Cancer Institute
Faculty of Medicine, Chulalongkorn University
Shanghai Chest Hospital
Shizuoka Cancer Center
Kanagawa Cancer Center Research Institute
Hanoi Medical University
Vajira Hospital
Hospital Municipal Dr. Bernardo A. Houssay
Hospitales Universitarios Regional y Virgen de la Victoria
Centro Regional Integrado de Oncologia
West China School of Medicine/West China Hospital of Sichuan University
Tongji Medical College of Huazhong University of Science and Technology
National Taiwan University Hospital
Chang Gung University
Samsung Medical Center, Sungkyunkwan university
AstraZeneca
Siriraj Hospital
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty of Medicine
Osaka International Cancer Institute
Faculty of Medicine, Chulalongkorn University
Shanghai Chest Hospital
Shizuoka Cancer Center
Kanagawa Cancer Center Research Institute
Hanoi Medical University
Vajira Hospital
Hospital Municipal Dr. Bernardo A. Houssay
Hospitales Universitarios Regional y Virgen de la Victoria
Centro Regional Integrado de Oncologia
Corresponding Author(s)
Other Contributor(s)
Abstract
Plain Language Summary: What is this summary about? We review current standard treatment for patients with non-small cell lung cancer (NSCLC) that has spread to nearby tissues and/or nearby parts of the immune system called lymph nodes (stage III) that could not be removed by surgery (unresectable), and had an EGFR mutation. The epidermal growth factor receptor (known as EGFR) is a type of protein present on the surface of some cells, which controls how cells grow and divide. Mutations in the EGFR gene can result in the development of lung cancer. We include a summary of results from the LAURA study, which evaluated osimertinib treatment for these patients. Osimertinib is a medicine that blocks the activity of mutated EGFR protein on cancer cells, causing cancer cell death and tumor shrinkage. The LAURA study focused on unresectable stage III EGFR-mutated NSCLC treated with chemoradiotherapy (a combination of a medicine and radiation therapy to kill cancer cells and shrink the tumor); if the cancer did not grow or spread during or after this treatment, patients were enrolled in LAURA and randomly assigned to receive osimertinib or placebo. What are the key takeaways? Osimertinib significantly increased the time that patients lived without the cancer growing or spreading (called progression-free survival). Patients who received osimertinib had the median progression-free survival extended by 33.6 months, compared with placebo. The median timepoint of progression-free survival is a type of average at which half of the patients were alive without the cancer growing or spreading. The most common side effects were lung inflammation from radiotherapy (radiation pneumonitis), diarrhea and rash, consistent with what we already know about osimertinib and chemoradiotherapy. What were the main conclusions reported by the researchers? Findings from the LAURA study led to regulatory approvals and guideline recommendations for using osimertinib to treat patients with unresectable stage III EGFR-mutated NSCLC, whose cancer has not grown or spread (progressed) during or after chemoradiotherapy. Clinical trial number: NCT03521154.